Inflammation and cancer: Till death tears them apart

Veterinary Journal

Volumn 205, Issue 2, 2015, Pages 161-174

  Raposo, T P ^a,b   Beirao B C B ^a   Pang, L Y ^a   Queiroga, F L ^b   Argyle, D J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

Author keywords

Cancer; Inflammation; Macrophages; Metastasis; Stem cells; Veterinary oncology

Indexed keywords

ANGIOPOIETIN; CELECOXIB; COLONY STIMULATING FACTOR 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; NONSTEROID ANTIINFLAMMATORY AGENT; RANTES; THYMIDINE PHOSPHORYLASE; VASCULOTROPIN; TUMOR MARKER;

AUTOIMMUNITY; CANCER THERAPY; CARCINOGENESIS; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE ASSOCIATION; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; IMMUNE DEFICIENCY; IMMUNE EVASION; IMMUNOREGULATION; IMMUNOSURVEILLANCE; INFECTION; INFLAMMATION; NEOPLASM; NONHUMAN; ONCOLOGY; PHENOTYPE; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; VETERINARY MEDICINE; ANIMAL; METABOLISM; METASTASIS; PATHOLOGY; PATHOPHYSIOLOGY; TUMOR INVASION; VETERINARY;

CANIS FAMILIARIS;

ANIMALS; BIOMARKERS, TUMOR; CARCINOGENESIS; INFLAMMATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS;

EID: 84937521344     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2015.04.015     Document Type: Review

References (181)

1. Aharinejad S., Paulus P., Sioud M., Hofmann M., Zins K., Schafer R., Stanley E.R., Abraham D. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Research 2004, 64:5378-5384.
2. Allenspach E.J., Maillard I., Aster J.C., Pear W.S. Notch signaling in cancer. Cancer Biology and Therapy 2002, 1:466-476.
3. Argyle D.J., Blacking T. From viruses to cancer stem cells: Dissecting the pathways to malignancy. The Veterinary Journal 2008, 177:311-323.
4. Atsumi T., Singh R., Sabharwal L., Bando H., Meng J., Arima Y., Yamada M., Harada M., Jiang J.J., Kamimura D., et al. Inflammation amplifier, a new paradigm in cancer biology. Cancer Research 2014, 74:8-14.
5. Baj-Krzyworzeka M., Baran J., Weglarczyk K., Szatanek R., Szaflarska A., Siedlar M., Zembala M. Tumour-derived microvesicles (TMV) mimic the effect of tumour cells on monocyte subpopulations. Anticancer Research 2010, 30:3515-3519.
6. Baj-Krzyworzeka M., Weglarczyk K., Mytar B., Szatanek R., Baran J., Zembala M. Tumour-derived microvesicles contain interleukin-8 and modulate production of chemokines by human monocytes. Anticancer Research 2011, 31:1329-1335.
7. Balkwill F. Cancer and the chemokine network. Nature Reviews. Cancer 2004, 4:540-550.
8. Balkwill F., Mantovani A. Inflammation and cancer: Back to Virchow?. The Lancet 2001, 357:539-545.
9. Balkwill F., Charles K.A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005, 7:211-217.
10. Bartocci A., Mastrogiannis D.S., Migliorati G., Stockert R.J., Wolkoff A.W., Stanley E.R. Macrophages specifically regulate the concentration of their own growth factor in the circulation. Proceedings of the National Academy of Sciences of the United States of America 1987, 84:6179-6183.
11. Beatty J. Viral causes of feline lymphoma: Retroviruses and beyond. The Veterinary Journal 2014, 201:174-180.
12. Ben-Neriah Y., Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nature Immunology 2011, 12:715-723.
13. Benoy I.H., Salgado R., Van D.P., Geboers K., Van M.E., Scharpe S., Vermeulen P.B., Dirix L.Y. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clinical Cancer Research 2004, 10:7157-7162.
14. Boria P.A., Murry D.J., Bennett P.F., Glickman N.W., Snyder P.W., Merkel B.L., Schlittler D.L., Mutsaers A.J., Thomas R.M., Knapp D.W. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. Journal of the American Veterinary Medical Association 2004, 224:388-394.
15. Boveri T. Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris. Journal of Cell Science 2008, 121:1-84.
16. Brien G., Trescol-Biemont M.C., Bonnefoy-Bérard N. Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis. Oncogene 2007, 26:5828-5832.
17. Bronte V., Serafini P., Apolloni E., Zanovello P. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. Journal of Immunotherapy 2001, 24:431-446.
18. Brown K.D. Transglutaminase 2 and NF-κB: An odd couple that shapes breast cancer phenotype. Breast Cancer Research and Treatment 2013, 137:329-336.
19. Calle E.E., Kaaks R. Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nature Reviews. Cancer 2004, 4:579-591.
20. Carnero A., Blanco-Aparicio C., Renner O., Link W., Leal J.F. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Current Cancer Drug Targets 2008, 8:187-198.
21. Carvalho M.I., Pires I., Prada J., Queiroga F.L. T-lymphocytic infiltrate in canine mammary tumours: Clinic and prognostic implications. In Vivo (Athens, Greece) 2011, 25:963-969.
22. Cerchietti L.C., Bonomi M.R., Navigante A.H., Castro M.A., Cabalar M.E., Roth B.M. Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases. Journal of Neurooncology 2005, 71:73-81.
23. Cervantes-Arias A., Pang L.Y., Argyle D.J. Epithelial-mesenchymal transition as a fundamental mechanism underlying the cancer phenotype. Veterinary and Comparative Oncology 2013, 11:169-184.
24. Chase D., McLauchlan G., Eckersall P.D., Pratschke J., Parkin T., Pratschke K. Acute phase protein levels in dogs with mast cell tumours and sarcomas. Veterinary Record 2012, 170:648.
25. Chaturvedi M.M., Sung B., Yadav V.R., Kannappan R., Aggarwal B.B. NF-κB addiction and its role in cancer: 'One size does not fit all'. Oncogene 2011, 30:1615-1630.
26. Chitu V., Stanley E.R. Colony-stimulating factor-1 in immunity and inflammation. Current Opinion in Immunology 2006, 18:39-48.
27. Chon E., McCartan L., Kubicek L.N., Vail D.M. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): A phase I dose-finding study. Veterinary and Comparative Oncology 2012, 10:184-193.
28. Cohen A.J., Pope C.A. Lung cancer and air pollution. Environmental Health Perspectives 1995, 103:219-224.
29. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 2009, 30:1073-1081.
30. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
31. Cross S.S., Hamdy F.C., Deloulme J.C., Rehman I. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 2005, 46:256-269.
32. Csermely P., Hodsagi J., Korcsmaros T., Modos D., Perez-Lopez A.R., Szalay K., Veres D.V., Lenti K., Wu L.Y., Zhang X.S. Cancer stem cells display extremely large evolvability: Alternating plastic and rigid networks as a potential mechanism: Network models, novel therapeutic target strategies, and the contributions of hypoxia, inflammation and cellular senescence. Seminars in Cancer Biology 2014, 30:42-51.
33. de Andres P.J., Illera J.C., Caceres S., Diez L., Perez-Alenza M.D., Pena L. Increased levels of interleukins 8 and 10 as findings of canine inflammatory mammary cancer. Veterinary Immunology and Immunopathology 2013, 152:245-251.
34. de Vos J., Ramos V.S., Noorman E., de Vos P. Primary frontal sinus squamous cell carcinoma in three dogs treated with piroxicam combined with carboplatin or toceranib. Veterinary and Comparative Oncology 2012, 10:206-213.
35. Das K.C., White C.W. Activation of NF-κB by antineoplastic agents. Journal of Biological Chemistry 1997, 272:14914-14920.
36. De Falco M., Lucariello A., Iaquinto S., Esposito V., Guerra G., De Luca A. Molecular mechanisms of Helicobacter pylori pathogenesis. Journal of Cell Physiology 2015, 10.1002/jcp.24933.
37. Debucquoy A., Roels S., Goethals L., Libbrecht L., Van C.E., Geboes K., Penninckx F., D'Hoore A., McBride W.H., Haustermans K. Double blind randomized phase II study with radiation+5-fluorouracil+/-celecoxib for resectable rectal cancer. Radiotherapy and Oncology 2009, 93:273-278.
38. Dethlefsen C., Hojfeldt G., Hojman P. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Research and Treatment 2013, 138:657-664.
39. Din F.V., Theodoratou E., Farrington S.M., Tenesa A., Barnetson R.A., Cetnarskyj R., Stark L., Porteous M.E., Campbell H., Dunlop M.G. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 2010, 59:1670-1679.
40. Dvorak H.F. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. New England Journal of Medicine 1986, 315:1650-1659.
41. Elmets C.A., Viner J.L., Pentland A.P., Cantrell W., Lin H.Y., Bailey H., Kang S., Linden K.G., Heffernan M., Duvic M., et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: A randomized, double-blind, placebo-controlled trial. Journal of the National Cancer Institute 2010, 102:1835-1844.
42. Elmslie R.E., Glawe P., Dow S.W. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. Journal of Veterinary Internal Medicine 2008, 22:1373-1379.
43. Escárcega R.O., Fuentes-Alexandro S., García-Carrasco M., Gatica A., Zamora A. The transcription factor nuclear factor-κB and cancer. Clinical Oncology 2007, 19:154-161.
44. Estrela-Lima A., Araujo M.S., Costa-Neto J.M., Teixeira-Carvalho A., Barrouin-Melo S.M., Cardoso S.V., Martins-Filho O.A., Serakides R., Cassali G.D. Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates. BMC Cancer 2010, 10:256.
45. Fabi A., Metro G., Papaldo P., Mottolese M., Melucci E., Carlini P., Sperduti I., Russillo M., Gelibter A., Ferretti G., et al. Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: Results of a phase II study with biomarker evaluation. Cancer Chemotherapy and Pharmacology 2008, 62:717-725.
46. Fang J.Y., Richardson B.C. The MAPK signalling pathways and colorectal cancer. The Lancet Oncology 2005, 6:322-327.
47. Fang W.B., Jokar I., Zou A., Lambert D., Dendukuri P., Cheng N. CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms. Journal of Biological Chemistry 2012, 287:36593-36608.
48. Francescone R., Hou V., Grivennikov S.I. Cytokines, IBD, and colitis-associated cancer. Inflammatory Bowel Disease 2015, 21:409-418.
49. Fujimoto H., Sangai T., Ishii G., Ikehara A., Nagashima T., Miyazaki M., Ochiai A. Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. International Journal of Cancer 2009, 125:1276-1284.
50. Gelaleti G.B., Jardim B.V., Leonel C., Moschetta M.G., Zuccari D.A. Interleukin-8 as a prognostic serum marker in canine mammary gland neoplasias. Veterinary Immunology and Immunopathology 2012, 146:106-112.
51. Ginestier C., Liu S., Diebel M.E., Korkaya H., Luo M., Brown M., Wicinski J., Cabaud O., Charafe-Jauffret E., Birnbaum D., et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. Journal of Clinical Investigation 2010, 120:485-497.
52. Greene S.N., Lucroy M.D., Greenberg C.B., Bonney P.L., Knapp D.W. Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder. Journal of the American Veterinary Medical Association 2007, 231:1056-1060.
53. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
54. Gupta S.C., Hevia D., Patchva S., Park B., Koh W., Aggarwal B.B. Upsides and downsides of reactive oxygen species for cancer: The roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxidants and Redox Signaling 2012, 16:1295-1322.
55. Hagemann T., Biswas S.K., Lawrence T., Sica A., Lewis C.E. Regulation of macrophage function in tumors: The multifaceted role of NF-κB. Blood 2009, 113:3139-3146.
56. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
57. Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell 2011, 144:646-674.
58. Hansen M.T., Forst B., Cremers N., Quagliata L., Ambartsumian N., Grum-Schwensen B., Klingelhofer J., Abdul-Al A., Herrmann P., Osterland M., et al. A link between inflammation and metastasis: Serum amyloid A1 and A3 induce metastasis, and are targets of metastasis-inducing S100A4. Oncogene 2014, 34:424-435.
59. Hashimoto S.I., Komuro I., Yamada M., Akagawa K.S. IL-10 inhibits granulocyte-macrophage colony-stimulating factor-dependent human monocyte survival at the early stage of the culture and inhibits the generation of macrophages. Journal of Immunology 2001, 167:3619-3625.
60. Heilmann R.M., Wright Z.M., Lanerie D.J., Suchodolski J.S., Steiner J.M. Measurement of urinary canine S100A8/A9 and S100A12 concentrations as candidate biomarkers of lower urinary tract neoplasia in dogs. Journal of Veterinary Diagnostic Investigation 2014, 26:104-112.
61. Hembruff S.L., Jokar I., Yang L., Cheng N. Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and -independent mechanisms. Neoplasia 2010, 12:425-433.
62. Henry C.J., McCaw D.L., Turnquist S.E., Tyler J.W., Bravo L., Sheafor S., Straw R.C., Dernell W.S., Madewell B.R., Jorgensen L., et al. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. Clinical Cancer Research 2003, 9:906-911.
63. Hiratsuka S., Ishibashi S., Tomita T., Watanabe A., Akashi-Takamura S., Murakami M., Kijima H., Miyake K., Aburatani H., Maru Y. Primary tumours modulate innate immune signalling to create pre-metastatic vascular hyperpermeability foci. Nature Communications 2013, 4:1853.
64. Hiscott J., Kwon H., Génin P. Hostile takeovers: Viral appropriation of the NF-κB pathway. Journal of Clinical Investigation 2001, 107:143-151.
65. Hiwatashi K., Tamiya T., Hasegawa E., Fukaya T., Hashimoto M., Kakoi K., Kashiwagi I., Kimura A., Inoue N., Morita R., et al. Suppression of SOCS3 in macrophages prevents cancer metastasis by modifying macrophage phase and MCP2/CCL8 induction. Cancer Letters 2011, 308:172-180.
66. Hoesel B., Schmid J.A. The complexity of NF-κB signaling in inflammation and cancer. Molecular Cancer 2013, 12:86.
67. Hou Z., Falcone D.J., Subbaramaiah K., Dannenberg A.J. Macrophages induce COX-2 expression in breast cancer cells: Role of IL-1β autoamplification. Carcinogenesis 2011, 32:695-702.
68. Hsiao Y.W., Liao K.W., Chung T.F., Liu C.H., Hsu C.D., Chu R.M. Interactions of host IL-6 and IFN-γ and cancer-derived TGF-β1 on MHC molecule expression during tumor spontaneous regression. Cancer Immunology, Immunotherapy 2008, 57:1091-1104.
69. Hsu R.Y., Chan C.H., Spicer J.D., Rousseau M.C., Giannias B., Rousseau S., Ferri L.E. LPS-induced TLR4 signaling in human colorectal cancer cells increases β1 integrin-mediated cell adhesion and liver metastasis. Cancer Research 2011, 71:1989-1998.
70. Ishioka K., Suzuki Y., Tajima K., Ohtaki S., Miyabe M., Takasaki M., Mori A., Momota Y., Azakami D., Sako T. Monocyte chemoattractant protein-1 in dogs affected with neoplasia or inflammation. Journal of Veterinary Medical Science 2012, 75:173-177.
71. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nature Reviews Cancer 2009, 9:239-252.
72. Kamradt T. Immunological tolerance. Immunology 2012, 307-321. Elsevier, St. Louis, MO, USA. Eighth Ed. D. Male, J. Brostoff, D. Roth, I. Roitt (Eds.).
73. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006, 441:431-436.
74. Karin M. The IκB kinase - a bridge between inflammation and cancer. Cell Research 2008, 18:334-342.
75. Keniry M., Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008, 27:5477-5485.
76. Kim J.H., Yu C.H., Yhee J.Y., Im K.S., Sur J.H. Lymphocyte infiltration, expression of interleukin (IL) -1, IL-6 and expression of mutated breast cancer susceptibility gene-1 correlate with malignancy of canine mammary tumours. Journal of Comparative Pathology 2010, 142:177-186.
77. Kim G., Ouzounova M., Quraishi A.A., Davis A., Tawakkol N., Clouthier S.G., Malik F., Paulson A.K., D'Angelo R.C., Korkaya S., et al. SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model. Oncogene 2014, 34:671-680.
78. Kim J.H., Frantz A.M., Anderson K.L., Graef A.J., Scott M.C., Robinson S., Sharkey L.C., O'Brien T.D., Dickerson E.B., Modiano J.F. Interleukin-8 promotes canine hemangiosarcoma growth by regulating the tumor microenvironment. Experimental Cell Research 2014, 323:155-164.
79. Kipanyula M.J., Seke Etet P.F., Vecchio L., Farahna M., Nukenine E.N., Nwabo Kamdje A.H. Signaling pathways bridging microbial-triggered inflammation and cancer. Cellular Signalling 2013, 25:403-416.
80. Knapp D.W., Richardson R.C., Bottoms G.D., Teclaw R., Chan T.C. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemotherapy and Pharmacology 1992, 29:214-218.
81. Knapp D.W., Richardson R.C., Chan T.C., Bottoms G.D., Widmer W.R., DeNicola D.B., Teclaw R., Bonney P.L., Kuczek T. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. Journal of Veterinary Internal Medicine 1994, 8:273-278.
82. Knapp D.W., Chan T.C., Kuczek T., Reagan W.J., Park B. Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. American Journal of Veterinary Research 1995, 56:801-805.
83. Knapp D.W., Henry C.J., Widmer W.R., Tan K.M., Moore G.E., Ramos-Vara J.A., Lucroy M.D., Greenberg C.B., Greene S.N., Abbo A.H., et al. Randomized trial of cisplatin versus firocoxib versus cisplatin/firocoxib in dogs with transitional cell carcinoma of the urinary bladder. Journal of Veterinary Internal Medicine 2013, 27:126-133.
84. Koizumi K., Hojo S., Akashi T., Yasumoto K., Saiki I. Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Science 2007, 98:1652-1658.
85. Krol M., Pawlowski K.M., Dolka I., Musielak O., Majchrzak K., Mucha J., Motyl T. Density of Gr1-positive myeloid precursor cells, p-STAT3 expression and gene expression pattern in canine mammary cancer metastasis. Veterinary Research Communications 2011, 35:409-423.
86. Krol M., Pawlowski K.M., Majchrzak K., Dolka I., Abramowicz A., Szyszko K., Motyl T. Density of tumor-associated macrophages (TAMs) and expression of their growth factor receptor MCSF-R and CD14 in canine mammary adenocarcinomas of various grade of malignancy and metastasis. Polish Journal of Veterinary Sciences 2011, 14:3-10.
87. Krol M., Majchrzak K., Mucha J., Homa A., Bulkowska M., Jakubowska A., Karwicka M., Pawlowski K.M., Motyl T. CSF-1R as an inhibitor of apoptosis and promoter of proliferation, migration and invasion of canine mammary cancer cells. BMC Veterinary Research 2013, 9:65.
88. Landskron G., De la Fuente M., Thuwajit P., Thuwajit C., Hermoso M.A. Chronic inflammation and cytokines in the tumor microenvironment. Journal of Immunology Research 2014, 2014:149185.
89. Lane P.J., McConnell F.M., Anderson G., Nawaf M.G., Gaspal F.M., Withers D.R. Evolving strategies for cancer and autoimmunity: Back to the future. Frontiers in Immunology 2014, 5:154.
90. Lejeune F.J., Monnier Y., Ruegg C. Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with cyclooxygenase-2 inhibitor. Melanoma Research 2006, 16:263-265.
91. Lentsch A.B., Shanley T.P., Sarma V., Ward P.A. In vivo suppression of NF-κB and preservation of IκBα by interleukin-10 and interleukin-13. Journal of Clinical Investigation 1997, 100:2443-2448.
92. Lewis C.E., Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Research 2006, 66:605-612.
93. Li S., Symonds A.L., Miao T., Sanderson I., Wang P. Modulation of antigen-specific T-cells as immune therapy for chronic infectious diseases and cancer. Frontiers in Immunology 2014, 5:293.
94. Li Z., Xu Q., Peng H., Cheng R., Sun Z., Ye Z. IFN-γ enhances HOS and U2OS cell lines susceptibility to γδ T cell-mediated killing through the Fas/Fas ligand pathway. International Immunopharmacology 2011, 11:496-503.
95. Liggett J.L., Zhang X., Eling T.E., Baek S.J. Anti-tumor activity of non-steroidal anti-inflammatory drugs: Cyclooxygenase-independent targets. Cancer Letters 2014, 346:217-224.
96. Lin E.Y., Li J.F., Gnatovskiy L., Deng Y., Zhu L., Grzesik D.A., Qian H., Xue X.N., Pollard J.W. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Research 2006, 66:11238-11246.
97. Lin C.S., Chen M.F., Wang Y.S., Chuang T.F., Chiang Y.L., Chu R.M. IL-6 restores dendritic cell maturation inhibited by tumor-derived TGF-β through interfering Smad 2/3 nuclear translocation. Cytokine 2013, 62:352-359.
98. Ling J., Kumar R. Crosstalk between NFkB and glucocorticoid signaling: A potential target of breast cancer therapy. Cancer Letters 2012, 322:119-126.
99. Liu W.H., Liu J.J., Wu J., Zhang L.L., Liu F., Yin L., Zhang M.M., Yu B. Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway. PLoS ONE 2013, 8:e55487.
100. Liu Y., Chen J.Q., Xie L., Wang J., Li T., He Y., Gao Y., Qin X., Li S. Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: A systematic review and meta-analysis. BMC Medicine 2014, 12:55.
101. Loberg R.D., Ying C., Craig M., Day L.L., Sargent E., Neeley C., Wojno K., Snyder L.A., Yan L., Pienta K.J. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Research 2007, 67:9417-9424.
102. Lu X., Kang Y. Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. Journal of Biological Chemistry 2009, 284:29087-29096.
103. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
104. Marconato L., Zini E., Lindner D., Suslak-Brown L., Nelson V., Jeglum A.K. Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder. Journal of the American Veterinary Medical Association 2011, 238:1004-1010.
105. Markowitz J., Wesolowski R., Papenfuss T., Brooks T.R., Carson W.E. Myeloid-derived suppressor cells in breast cancer. Breast Cancer Research and Treatment 2013, 140:13-21.
106. Maruyama K., Ii M., Cursiefen C., Jackson D.G., Keino H., Tomita M., Van R.N., Takenaka H., D'Amore P.A., Stein-Streilein J., et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. Journal of Clinical Investigation 2005, 115:2363-2372.
107. McMillan S.K., Boria P., Moore G.E., Widmer W.R., Bonney P.L., Knapp D.W. Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. Journal of the American Veterinary Medical Association 2011, 239:1084-1089.
108. Melichar B., Študentova H., Kalábová H., Vitásková D., Čermáková P., Hornychová H., Ryška A. Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy. Anticancer Research 2014, 34:1115-1125.
109. Mitchell R.A., Bucala R. Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Seminars in Cancer Biology 2000, 10:359-366.
110. Mitchem J.B., Brennan D.J., Knolhoff B.L., Belt B.A., Zhu Y., Sanford D.E., Belaygorod L., Carpenter D., Collins L., Piwnica-Worms D., et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Research 2013, 73:1128-1141.
111. Mkaouar L., Endo Y., Mochizuki M., Nishimura R., Sasaki N., Nakagawa T. Effects of NF-κB expression and its inhibition on canine mammary cancer cell lines in an immunodeficient mice model. Journal of Veterinary Medical Science 2011, 73:1539-1546.
112. Mkaouar L., Endo Y., Jun H.X., Lee S.J., Jaroensong T., Mochizuki M., Uchida K., Nakayama H., Sasaki N., Nakagawa T. Relationship between NF-κB expression and malignancy of canine mammary gland tumor tissues. Journal of Veterinary Medical Science 2012, 74:713-718.
113. Modiano J.F., Bellgrau D., Cutter G.R., Lana S.E., Ehrhart N.P., Ehrhart E., Wilke V.L., Charles J.B., Munson S., Scott M.C., et al. Inflammation, apoptosis, and necrosis induced by neoadjuvant Fas ligand gene therapy improves survival of dogs with spontaneous bone cancer. Molecular Therapy 2012, 20:2234-2243.
114. Mudaliar M.A., Haggart R.D., Miele G., Sellar G., Tan K.A., Goodlad J.R., Milne E., Vail D.M., Kurzman I., Crowther D., et al. Comparative gene expression profiling identifies common molecular signatures of NF-κB activation in canine and human diffuse large B cell lymphoma (DLBCL). PLoS ONE 2013, 8:e72591.
115. + T cell cytotoxicity. Bioessays: News and Reviews in Molecular, Cellular and Developmental Biology 2013, 35:623-631.
116. Mumm J.B., Emmerich J., Zhang X., Chan I., Wu L., Mauze S., Blaisdell S., Basham B., Dai J., Grein J., et al. IL-10 elicits IFNγ-dependent tumor immune surveillance. Cancer Cell 2011, 20:781-796.
117. Munro A.J., Lain S., Lane D.P. P53 abnormalities and outcomes in colorectal cancer: A systematic review. British Journal of Cancer 2005, 92:434-444.
118. Muranski P., Restifo N.P. Essentials of Th17 cell commitment and plasticity. Blood 2013, 121:2402-2414.
119. Mutsaers A.J., Glickman N.W., DeNicola D.B., Widmer W.R., Bonney P.L., Hahn K.A., Knapp D.W. Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs. Journal of the American Veterinary Medical Association 2002, 220:1813-1817.
120. Nakanishi C., Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nature Reviews. Cancer 2005, 5:297-309.
121. Nakao S., Kuwano T., Tsutsumi-Miyahara C., Ueda S., Kimura Y.N., Hamano S., Sonoda K.H., Saijo Y., Nukiwa T., Strieter R.M., et al. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1β-induced neovascularization and tumor growth. Journal of Clinical Investigation 2005, 115:2979-2991.
122. Nikolic N.L., Kjelgaard-Hansen M., Kristensen A.T. Monocyte chemotactic protein-1 and other inflammatory parameters in Bernese mountain dogs with disseminated histiocytic sarcoma. The Veterinary Journal 2013, 198:424-428.
123. Obeid E., Nanda R., Fu Y.X., Olopade O.I. The role of tumor-associated macrophages in breast cancer progression. International Journal of Oncology 2013, 43:5-12.
124. Ohnishi S., Ma N., Thanan R., Pinlaor S., Hammam O., Murata M., Kawanishi S. DNA damage in inflammation-related carcinogenesis and cancer stem cells. Oxidative Medicine and Cellular Longevity 2013, 2013:387014.
125. Ohno S., Ohno Y., Suzuki N., Kamei T., Koike K., Inagawa H., Kohchi C., Soma G., Inoue M. Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Research 2004, 24:3335-3342.
126. + T cell cytokine gene and protein expression in duodenal mucosa of dogs with inflammatory bowel disease. Journal of Veterinary Medical Science 2014, 76:409-414.
127. Osaki M., Oshimura M., Ito H. PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis: An International Journal on Programmed Cell Death 2004, 9:667-676.
128. Pai R., Soreghan B., Szabo I.L., Pavelka M., Baatar D., Tarnawski A.S. Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nature Medicine 2002, 8:289-293.
129. Pang L.Y., Gatenby E.L., Kamida A., Whitelaw B.A., Hupp T.R., Argyle D.J. Global gene expression analysis of canine osteosarcoma stem cells reveals a novel role for COX-2 in tumour initiation. PLoS ONE 2014, 9:e83144.
130. Paoloni M., Davis S., Lana S., Withrow S., Sangiorgi L., Picci P., Hewitt S., Triche T., Meltzer P., Khanna C. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics 2009, 10:625.
131. Patsialou A., Wyckoff J., Wang Y., Goswami S., Stanley E.R., Condeelis J.S. Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor. Cancer Research 2009, 69:9498-9506.
132. Pei X.H., Nakanishi Y., Takayama K., Bai F., Hara N. Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells. British Journal of Cancer 1999, 79:40-46.
133. Perry J.A., Thamm D.H., Eickhoff J., Avery A.C., Dow S.W. Increased monocyte chemotactic protein-1 concentration and monocyte count independently associate with a poor prognosis in dogs with lymphoma. Veterinary and Comparative Oncology 2011, 9:55-64.
134. Polverini P.J., Leibovich S.J. Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Laboratory Investigation 1984, 51:635-642.
135. Prior I.A., Lewis P.D., Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Research 2012, 72:2457-2467.
136. Qian B., Deng Y., Im J.H., Muschel R.J., Zou Y., Li J., Lang R.A., Pollard J.W. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE 2009, 4:e6562.
137. Qian B.Z., Li J., Zhang H., Kitamura T., Zhang J., Campion L.R., Kaiser E.A., Snyder L.A., Pollard J.W. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475:222-225.
138. Qian B.Z., Pollard J.W. New tricks for metastasis-associated macrophages. Breast Cancer Research 2012, 14:316.
139. Raposo T.P., Pires I., Carvalho M.I., Prada J., Argyle D.J., Queiroga F.L. Tumour-associated macrophages are associated with vascular endothelial growth factor expression in canine mammary tumours. Veterinary and Comparative Oncology 2013, 10.1111/vco.12067.
140. Raposo T., Gregorio H., Pires I., Prada J., Queiroga F.L. Prognostic value of tumour-associated macrophages in canine mammary tumours. Veterinary and Comparative Oncology 2014, 12:10-19.
141. Robat C., Burton J., Thamm D., Vail D. Retrospective evaluation of doxorubicin-piroxicam combination for the treatment of transitional cell carcinoma in dogs. Journal of Small Animal Practice 2013, 54:67-74.
142. Robinson B.D., Sica G.L., Liu Y.F., Rohan T.E., Gertler F.B., Condeelis J.S., Jones J.G. Tumor microenvironment of metastasis in human breast carcinoma: A potential prognostic marker linked to hematogenous dissemination. Clinical Cancer Research 2009, 15:2433-2441.
143. Saito T., Tamura D., Asano R. Usefulness of selective COX-2 inhibitors as therapeutic agents against canine mammary tumors. Oncology Reports 2014, 31:1637-1644.
144. Schmidt B.R., Glickman N.W., DeNicola D.B., de Gortari A.E., Knapp D.W. Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. Journal of the American Veterinary Medical Association 2001, 218:1783-1786.
145. Schwandt A., Garcia J.A., Elson P., Wyckhouse J., Finke J.H., Ireland J., Triozzi P., Zhou M., Dreicer R., Rini B.I. Clinical and immunomodulatory effects of celecoxib plus interferon-α in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining. Journal of Clinical Immunology 2011, 31:690-698.
146. Sester D.P., Beasley S.J., Sweet M.J., Fowles L.F., Cronau S.L., Stacey K.J., Hume D.A. Bacterial/CpG DNA down-modulates colony stimulating factor-1 receptor surface expression on murine bone marrow-derived macrophages with concomitant growth arrest and factor-independent survival. Journal of Immunology 1999, 163:6541-6550.
147. Sheng H., Shao J., Washington M.K., DuBois R.N. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. Journal of Biological Chemistry 2001, 276:18075-18081.
148. Shigdar S., Li Y., Bhattacharya S., O'Connor M., Pu C., Lin J., Wang T., Xiang D., Kong L., Wei M.Q., et al. Inflammation and cancer stem cells. Cancer Letters 2014, 345:271-278.
149. Sica A., Schioppa T., Mantovani A., Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. European Journal of Cancer 2006, 42:717-727.
150. Singh B., Berry J.A., Vincent L.E., Lucci A. Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer. Journal of Surgical Research 2006, 134:44-51.
151. Singh J.K., Farnie G., Bundred N.J., Simoes B.M., Shergill A., Landberg G., Howell S.J., Clarke R.B. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clinical Cancer Research 2013, 19:643-656.
152. Singh J.K., Simoes B.M., Howell S.J., Farnie G., Clarke R.B. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Research 2013, 15:210.
153. Sinha P., Clements V.K., Fulton A.M., Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Research 2007, 67:4507-4513.
154. Soerjomataram I., Lortet-Tieulent J., Parkin D.M., Ferlay J., Mathers C., Forman D., Bray F. Global burden of cancer in 2008: A systematic analysis of disability-adjusted life-years in 12 world regions. The Lancet 2012, 380:1840-1850.
155. Solinas G., Germano G., Mantovani A., Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. Journal of Leukocyte Biology 2009, 86:1065-1073.
156. Sorenmo K.U., Goldschmidt M.H., Shofer F.S., Goldkamp C., Ferracone J. Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma. Veterinary and Comparative Oncology 2004, 2:13-23.
157. Swierczak A., Cook A.D., Lenzo J.C., Restall C.M., Doherty J.P., Anderson R.L., Hamilton J.A. The promotion of breast cancer metastasis caused by inhibition of CSF-1R/CSF-1 signaling is blocked by targeting the G-CSF receptor. Cancer Immunology Research 2014, 2:765-776.
158. Talmadge J.E., Donkor M., Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer and Metastasis Reviews 2007, 26:373-400.
159. Taulescu M.A., Valentine B.A., Amorim I., Gartner F., Dumitrascu D.L., Gal A.F., Sevastre B., Catoi C. Histopathological features of canine spontaneous non-neoplastic gastric polyps - a retrospective study of 15 cases. Histology and Histopathology 2014, 29:65-75.
160. Thun M.J., Henley S.J., Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. Journal of the National Cancer Institute 2002, 94:252-266.
161. Tsuyada A., Chow A., Wu J., Somlo G., Chu P., Loera S., Luu T., Li A.X., Wu X., Ye W., et al. CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Research 2012, 72:2768-2779.
162. Ueno T., Toi M., Saji H., Muta M., Bando H., Kuroi K., Koike M., Inadera H., Matsushima K. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clinical Cancer Research 2000, 6:3282-3289.
163. Vakkila J., Lotze M.T. Inflammation and necrosis promote tumour growth. Nature Reviews Immunology 2004, 4:641-648.
164. Vazquez-Martin A., Colomer R., Menendez J.A. Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. European Journal of Cancer 2007, 43:1117-1124.
165. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
166. Vinothini G., Balachandran C., Nagini S. Evaluation of molecular markers in canine mammary tumors: Correlation with histological grading. Oncology Research 2009, 18:193-201.
167. Waris G., Ahsan H. Reactive oxygen species: Role in the development of cancer and various chronic conditions. Journal of Carcinogenesis 2006, 5:14.
168. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clinical Cancer Research 2008, 14:6735-6741.
169. Wolf M.J., Hoos A., Bauer J., Boettcher S., Knust M., Weber A., Simonavicius N., Schneider C., Lang M., Sturzl M., et al. Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Cancer Cell 2012, 22:91-105.
170. Wolff C., Malinowsky K., Berg D., Schragner K., Schuster T., Walch A., Bronger H., Hofler H., Becker K.F. Signalling networks associated with urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in breast cancer tissues: New insights from protein microarray analysis. Journal of Pathology 2011, 223:54-63.
171. Wu X., Cai M., Ji F., Lou L.M. The impact of COX-2 on invasion of osteosarcoma cell and its mechanism of regulation. Cancer Cell International 2014, 14:27.
172. Wyckoff J.B., Wang Y., Lin E.Y., Li J.F., Goswami S., Stanley E.R., Segall J.E., Pollard J.W., Condeelis J. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Research 2007, 67:2649-2656.
173. Xiong H., Zhang Z.G., Tian X.Q., Sun D.F., Liang Q.C., Zhang Y.J., Lu R., Chen Y.X., Fang J.Y. Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia 2008, 10:287-297.
174. Yao X., Huang J., Zhong H., Shen N., Faggioni R., Fung M., Yao Y. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacology and Therapeutics 2014, 141:125-139.
175. Zaidi M.R., Merlino G. The two faces of interferon-γ in cancer. Clinical Cancer Research 2011, 17:6118-6124.
176. Zarogoulidis P., Yarmus L., Darwiche K., Walter R., Huang H., Li Z., Zaric B., Tsakiridis K., Zarogoulidis K. Interleukin-6 cytokine: A multifunctional glycoprotein for cancer. Immunome Research 2013, 9:16535.
177. Zeisberger S.M., Odermatt B., Marty C., Zehnder-Fjallman A.H., Ballmer-Hofer K., Schwendener R.A. Clodronate-liposome-mediated depletion of tumour-associated macrophages: A new and highly effective antiangiogenic therapy approach. British Journal of Cancer 2006, 95:272-281.
178. Zhang J., Patel L., Pienta K.J. Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Progress in Molecular Biology and Translational Science 2010, 95:31-53.
179. Zhong H., Gutkin D.W., Han B., Ma Y., Keskinov A.A., Shurin M.R., Shurin G.V. Origin and pharmacological modulation of tumor-associated regulatory dendritic cells. International Journal of Cancer 2014, 134:2633-2645.
180. Zubair A., Frieri M. Role of nuclear factor-κB in breast and colorectal cancer. Current Allergy and Asthma Reports 2013, 13:44-49.
181. Zuccari D.A., Castro R., Gelaleti G.B., Mancini U.M. Interleukin-8 expression associated with canine mammary tumors. Genetics and Molecular Research 2011, 10:1522-1532.